Traditional Chinese medicine composition and its use in the preparation of products for improving hair loss

Abstract

The application provides a traditional Chinese medicine composition and application thereof in preparation of a product for improving alopecia. The traditional Chinese medicine composition comprises medlar, jujube, tuckahoe, sago palm seed, longan aril, mulberry fruit and lotus seed. The application can solve the problem of limited treatment effect of the prior art in improving alopecia and is suitable for the field of anti-alopecia drugs.

Description

Technical Field

[0001] This invention relates to the field of anti-hair loss drugs, and more specifically, to a traditional Chinese medicine composition and its application in the preparation of products that improve hair loss. Background Technology

[0002] Hair loss, especially androgenetic alopecia (AGA), has become a major public health issue affecting personal appearance and mental health. The pathogenesis of AGA is closely related to the excessive accumulation of dihydrotestosterone (DHT) in hair follicles. DHT-induced follicle shrinkage and growth cycle disruption directly lead to hair thinning and even loss, disrupting the scalp's ecological balance. With increasing societal emphasis on individual appearance, the demand for hair loss prevention and regrowth products is showing a significant upward trend. However, current solutions mostly fall into two categories: oral medications and topical preparations.

[0003] In oral treatment, finasteride is favored because it can inhibit the activity of 5α-reductase and reduce DHT production, thereby alleviating hair loss symptoms to some extent. However, the use of finasteride has potential side effects such as sexual dysfunction, and its effects may not be visible for at least 3-6 months, and hair loss may even recur after discontinuation of the drug.

[0004] Topical medications, such as minoxidil, can stimulate hair follicle regeneration and promote hair growth in the short term, but they struggle to address the root cause of hair loss—the internal regulation of DHT. Furthermore, widely available anti-hair loss shampoos and serums primarily focus on improving the scalp environment, lacking the ability to deeply repair hair follicles and activate hair regrowth mechanisms. This limits the overall treatment effectiveness and makes it difficult to truly reverse or maintain hair recovery in AGA patients in the long term. Summary of the Invention

[0005] The main objective of this invention is to provide a traditional Chinese medicine composition and its application in the preparation of products for improving hair loss, so as to solve the problem of limited therapeutic effects of hair loss improvement in the prior art.

[0006] To achieve the above objectives, according to a first aspect of the present invention, an application of a traditional Chinese medicine composition in the preparation of a product for improving hair loss is provided; the traditional Chinese medicine composition includes wolfberry, jujube, poria cocos, coix seed, longan pulp, mulberry, and lotus seed.

[0007] Further, by weight, the traditional Chinese medicine composition includes 1-5 parts of Poria cocos, 0.5-3 parts of Lycium barbarum, 0.5-3 parts of Morus alba, 0.5-3 parts of Longan aril, 0.01-2 parts of Coix lacryma-jobi, 0.01-2 parts of Nelumbo nucifera, and 0.01-2 parts of Ziziphus jujuba; preferably, the traditional Chinese medicine composition includes Lycium barbarum, Ziziphus jujuba, Poria cocos, Coix lacryma-jobi, Longan aril, Morus alba, Auricularia auricula-judae, and Nelumbo nucifera.

[0008] Preferably, by weight, the traditional Chinese medicine composition includes 0.5-4 parts of black fungus, 1-5 parts of poria cocos, 0.5-3 parts of wolfberry, 0.5-3 parts of mulberry, 0.5-3 parts of longan pulp, 0.01-2 parts of coix seed, 0.01-2 parts of lotus seed and 0.01-2 parts of jujube;

[0009] Preferably, the traditional Chinese medicine composition comprises, by weight, 2-4 parts of black fungus, 1-3 parts of poria cocos, 1-3 parts of wolfberry, 1-3 parts of mulberry, 0.5-2 parts of longan pulp, 0.05-0.2 parts of coix seed, 0.05-2 parts of lotus seed and 0.05-2 parts of jujube.

[0010] Furthermore, improving hair loss includes increasing one or more of the following indicators: hair quantity, hair length, hair follicle width, or skin thickness.

[0011] Furthermore, improving hair loss includes regulating any one or more of the following indicators: upregulating the expression of cell proliferation-active factors, downregulating the expression of apoptosis-related factors, downregulating the secretion level of dihydrotestosterone, upregulating the expression of β-catenin, downregulating the expression of glycogen synthesis kinase 3β, promoting cell proliferation, increasing the level of vascular endothelial growth factor, decreasing the level of androgen receptors, and decreasing the level of inflammatory factors; preferably, the inflammatory factors include one or more of interleukin-1, interleukin-6, or TGF-β1.

[0012] Furthermore, the dosage form of the product includes oral preparations; preferably, oral preparations include granules, tablets, capsules, solid beverages, or oral liquids.

[0013] To achieve the above objectives, according to a second aspect of the present invention, an application of a traditional Chinese medicine composition in the preparation of a product for increasing hair follicle thickness is provided; the traditional Chinese medicine composition includes wolfberry, jujube, poria cocos, coix seed, longan pulp, mulberry, and lotus seed.

[0014] To achieve the above objectives, according to a third aspect of the present invention, an application of a traditional Chinese medicine composition in the preparation of a product for increasing skin thickness is provided; the traditional Chinese medicine composition includes wolfberry, jujube, poria cocos, coix seed, longan pulp, mulberry, and lotus seed.

[0015] To achieve the above objectives, according to a fourth aspect of the present invention, an application of a traditional Chinese medicine composition in the preparation of a product for promoting hair growth is provided; the traditional Chinese medicine composition includes wolfberry, jujube, poria cocos, coix seed, longan pulp, mulberry, and lotus seed.

[0016] To achieve the above objectives, according to a fifth aspect of the present invention, there is provided an application of a composition in the preparation of a product for improving hair loss, the composition comprising composition A and composition B; wherein composition A comprises wolfberry, jujube, poria cocos, coix seed, longan pulp, mulberry, and lotus seed; and composition B comprises one or more of arborvitae leaf, fleeceflower root, anemarrhena rhizome, eclipta prostrata, sophora flavescens root, saposhnikovia root, phellodendron bark, rehmannia root, or flaxseed.

[0017] Further, in a preferred embodiment, the above composition B includes Platycladus orientalis leaves, Polygonum multiflorum, Anemarrhena asphodeloides, Eclipta prostrata, Sophora flavescens, Saposhnikovia divaricata, Phellodendron chinense, Rehmannia glutinosa, and flaxseed; preferably, the above composition B includes 0.1-3 parts of Platycladus orientalis leaves, 0.1-2.5 parts of Polygonum multiflorum, 0.05-2 parts of Anemarrhena asphodeloides, 0.01-0.15 parts of Eclipta prostrata, 0.005-0.1 parts of Sophora flavescens, 0.01-0.15 parts of Saposhnikovia divaricata, 0.01-0.15 parts of Phellodendron chinense, 0.01-0.2 parts of Rehmannia glutinosa, and 0.001-1 parts of flaxseed. Preferably, composition A includes wolfberry, jujube, poria cocos, coix seed, longan pulp, mulberry, black fungus, and lotus seed; preferably, by weight, composition A includes 0.5-4 parts black fungus, 1-5 parts poria cocos, 0.5-3 parts wolfberry, 0.5-3 parts mulberry, 0.5-3 parts longan pulp, 0.01-2 parts coix seed, 0.01-2 parts lotus seed, and 0.01-2 parts jujube; preferably, by weight, composition A includes 2-4 parts black fungus, 1-3 parts poria cocos, 1-3 parts wolfberry, 1-3 parts mulberry, 0.5-2 parts longan pulp, 0.05-0.2 parts coix seed, 0.05-2 parts lotus seed, and 0.05-2 parts jujube.

[0018] By applying the technical solution of this invention, a product for improving hair loss is prepared by using a traditional Chinese medicine composition including wolfberry, jujube, poria cocos, coix seed, longan pulp, mulberry, and lotus seed. This product can increase the width of hair follicles or the thickness of the scalp. It also leverages the mild and multi-target properties of traditional Chinese medicine to improve hair loss from multiple aspects. Furthermore, it is safe and has no side effects, thus providing patients with a stable, safe, and effective treatment plan for improving hair loss. Attached Figure Description

[0019] The accompanying drawings, which form part of this application, are used to provide a further understanding of the invention. The illustrative embodiments of the invention and their descriptions are used to explain the invention and do not constitute an undue limitation of the invention. In the drawings:

[0020] Figure 1The image shows the morphological appearance of the mouse dorsal skin of Test Example 1 in this application.

[0021] Figure 2 The diagram shows a statistical chart of the width of hair follicles on the back of a mouse, as in Test Example 1 of this application.

[0022] Figure 3 The graph shows the thickness of the mouse back skin in Test Example 1 of this application.

[0023] Figure 4 The diagram shows the morphological changes in the skin and hair growth of each group of mice in Test Example 1 of this application.

[0024] Figure 5 A statistical graph showing the positive rate of Ki67 staining in mouse dorsal skin tissue of Test Example 1 in this application is shown.

[0025] Figure 6 A statistical graph showing the positive rate of Tunel in mouse dorsal skin tissue of Test Example 1 in this application is presented.

[0026] Figure 7 The statistical graph of serum DHT secretion levels in mice from Test Example 1 of this application is shown.

[0027] Figure 8 The statistical graph of β-catenin expression level in mouse cells of Test Example 1 of this application is shown.

[0028] Figure 9 The graph shows the expression level of GSK3β in mouse cells of Test Example 1 of this application.

[0029] Figure 10 The diagram shows a false positive result of microscopic observation of a sample concentration of 0.5% in Test Example 1 of this application for cell safety testing. Detailed Implementation

[0030] It should be noted that, unless otherwise specified, the embodiments and features described in this application can be combined with each other. The present invention will now be described in detail with reference to the embodiments.

[0031] As mentioned in the background section, existing treatments for AGA alopecia include oral finasteride, which can alleviate symptoms to some extent, but is accompanied by strong side effects, and symptoms often recur after discontinuation. While commonly used topical minoxidil can stimulate hair follicle regeneration and promote hair growth in a short time, it is difficult to target DHT levels within the body, thus failing to fundamentally improve alopecia. Therefore, in this application, the inventors attempted to develop a novel traditional Chinese medicine composition that can effectively improve AGA alopecia, increase hair follicle width and scalp thickness, and reduce DHT secretion levels, thus proposing a series of protective measures in this application.

[0032] In a first typical embodiment of this application, an application of a traditional Chinese medicine composition in the preparation of a product for improving hair loss is provided; the traditional Chinese medicine composition includes wolfberry, jujube, poria cocos, coix seed, longan pulp, mulberry, and lotus seed.

[0033] Goji berries: Goji berries are sweet and neutral in nature, and enter the liver and kidney meridians. They have the effects of nourishing the liver and kidneys, improving eyesight, and moistening the lungs. They are often used to treat symptoms such as blurred vision, soreness of the waist and knees, dizziness, and tinnitus.

[0034] Jujubes: Jujubes are sweet and warm in nature. They mainly enter the spleen and stomach meridians and can replenish qi and blood, and calm the mind. They are suitable for symptoms such as pale complexion, fatigue, and insomnia caused by spleen and stomach weakness and insufficient qi and blood.

[0035] Poria cocos: Poria cocos is sweet in taste and neutral in nature. It enters the spleen and heart meridians and has the effects of promoting diuresis and removing dampness, strengthening the spleen and calming the mind. It is often used to treat problems such as edema, difficulty in urination, and spleen deficiency with dampness.

[0036] Job's tears: Job's tears are sweet, bland and cool in nature. They mainly act on the spleen, lung and bladder meridians and have the effects of strengthening the spleen and removing dampness, clearing heat and detoxifying.

[0037] Longan pulp: Longan pulp is sweet and warm in nature, and enters the heart and spleen meridians. It can nourish the heart and spleen, replenish qi and blood, and calm the mind. It is suitable for symptoms such as memory loss, anemia, and neurasthenia caused by insufficient heart blood and spleen deficiency.

[0038] Mulberry: Mulberry is sweet and sour in taste and cold in nature. It mainly acts on the liver and kidney meridians and has the functions of nourishing yin and tonifying the kidney, moistening the intestines and relieving constipation. It is often used to treat kidney deficiency, lower back pain, constipation and liver and kidney yin deficiency.

[0039] Lotus seeds: Lotus seeds are sweet and astringent in taste and neutral in nature. They enter the spleen, kidney, and heart meridians. They can tonify the spleen and stop diarrhea, nourish the heart and strengthen the kidneys. They are suitable for symptoms such as chronic diarrhea due to spleen deficiency, palpitations, insomnia, seminal emission, and premature ejaculation.

[0040] Existing technologies for treating hair loss, especially AGA (aesthetically pleasing hair loss), have limitations in that they cannot balance the side effects of drug treatment, fail to achieve long-term stable hair growth, and rely on a single treatment method. These constitute significant challenges currently facing the field of hair loss prevention and hair regrowth. In the herbal composition of this application, through compatibility, the aforementioned components can synergistically exert a comprehensive effect of promoting hair follicle health and hair regrowth potential. When the herbal composition of this application is applied to prevent and treat hair loss, it can not only increase the width of hair follicles and the thickness of the skin, inhibit DHT production, and improve AGA hair loss, but also comprehensively promote the proliferation and differentiation of hair follicle stem cells, enhance hair follicle vitality, and reduce hair follicle cell apoptosis, leveraging the mild and multi-target characteristics of traditional Chinese medicine.

[0041] The traditional Chinese medicine composition disclosed in this application provides a safer, longer-lasting, and less side-effect-prone treatment option for hair loss, especially androgenetic alopecia. By utilizing the advantages of traditional Chinese medicine, it addresses the limitations of current hair loss treatments in terms of effectiveness and single mechanism of action, thus promoting the modern application of traditional Chinese medicine in the field of hair loss prevention and hair regrowth.

[0042] In a preferred embodiment, the traditional Chinese medicine composition, by weight, comprises 1-5 parts of Poria cocos (including but not limited to 1, 2, 3, 4, or 5 parts), 0.5-3 parts of Lycium barbarum (including but not limited to 0.5, 1, 2, or 3 parts), 0.5-3 parts of Morus alba (including but not limited to 0.5, 1, 2, or 3 parts), 0.5-3 parts of Longan aril (including but not limited to 0.5, 1, 2, or 3 parts), 0.01-2 parts of Coix lacryma-jobi (including but not limited to 0.01, 0.02, 0.03, 0.04, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 1, or 2 parts), and 0.01-2 parts of lotus seed (packaged). The ingredients include, but are not limited to, 0.01, 0.02, 0.03, 0.04, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 1 or 2 parts) and jujubes (including but not limited to 0.01, 0.02, 0.03, 0.04, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 1 or 2 parts); preferably, by weight, the traditional Chinese medicine composition includes 2-4 parts of black fungus, 1-3 parts of poria cocos, 1-3 parts of wolfberry, 1-3 parts of mulberry, 0.5-2 parts of longan pulp, 0.05-0.2 parts of coix seed, 0.05-2 parts of lotus seed and 0.05-2 parts of jujube.

[0043] In a preferred embodiment, the traditional Chinese medicine composition includes wolfberry, jujube, poria cocos, coix seed, longan pulp, mulberry, black fungus, and lotus seed; preferably, by weight, the traditional Chinese medicine composition includes 0.5-4 parts of black fungus (including but not limited to 0.5, 1, 2, 3, or 4 parts), 1-5 parts of poria cocos, 0.5-3 parts of wolfberry, 0.5-3 parts of mulberry, 0.5-3 parts of longan pulp, 0.01-2 parts of coix seed, 0.01-2 parts of lotus seed, and 0.01-2 parts of jujube;

[0044] Preferably, the traditional Chinese medicine composition comprises, by weight, 2-4 parts of black fungus, 1-3 parts of poria cocos, 1-3 parts of wolfberry, 1-3 parts of mulberry, 0.5-2 parts of longan pulp, 0.05-0.2 parts of coix seed, 0.05-2 parts of lotus seed and 0.05-2 parts of jujube.

[0045] The traditional Chinese medicine composition of this application also includes black fungus, which has a dry taste and neutral properties. It enters the lung, spleen, large intestine and liver meridians and has the functions of replenishing qi and blood, moistening the lungs, stopping bleeding and lowering blood pressure. It is often used for symptoms such as qi deficiency and blood deficiency, and chronic cough.

[0046] This application precisely controls the components in the above-mentioned traditional Chinese medicine composition within the aforementioned range, so that the components, under their interaction, neither antagonize each other nor synergistically exert their advantages. The overall medicinal properties are mild and safe, which can effectively improve hair loss problems and open up a more comprehensive, lasting, safe and stable path for the prevention and treatment of androgenetic alopecia (AGA).

[0047] Optionally, the traditional Chinese medicine composition may also include 1-5 parts by weight of soybean peptides. Soybean peptides are peptides obtained by hydrolyzing soybean protein through soybean enzymes. They have functions such as inhibiting cholesterol and promoting lipid metabolism and are a commonly used material for health foods in the prior art.

[0048] In a preferred embodiment, improving hair loss includes increasing any one or more of the following indicators: hair quantity, hair length, hair follicle width, or scalp skin thickness.

[0049] In a preferred embodiment, improving hair loss includes regulating any one or more of the following indicators: upregulating the expression of cell proliferation-proliferating factors, downregulating cell apoptosis levels, downregulating dihydrotestosterone secretion levels, upregulating β-catenin expression, downregulating glycogen synthesis kinase 3β expression, promoting cell proliferation (CCK-8 assay), increasing vascular endothelial growth factor (VEGF) levels, decreasing androgen receptor levels, and decreasing inflammatory factor levels; preferably, the inflammatory factors include one or more of interleukin-1, interleukin-6, or TGF-β1.

[0050] Ki67 is a marker of cell proliferation, and its expression level reflects the strength of hair follicle cell proliferation activity, making it an important indicator for evaluating the effectiveness of hair loss prevention.

[0051] A higher Tunel positivity rate indicates a more severe degree of cell apoptosis.

[0052] β-catenin, or β-catenin, is a key component of the Wnt signaling pathway. It maintains stem cell activity, upregulates the expression of cyclins, and promotes stem cell proliferation. β-catenin can upregulate the expression of the anti-apoptotic protein Bcl-2, downregulate apoptosis in hair matrix cells and outer root sheath cells, and prolong hair follicle lifespan.

[0053] GSK3β (glycogen synthesis kinase 3β) is a negative regulator of the Wnt signaling pathway. Increased GSK3β expression leads to downregulation of hair follicle stem cell proliferation, thereby downregulating hair growth.

[0054] The CCK-8 assay (Cell Counting Kit-8) is an experimental method for assessing cell proliferation capacity. It reflects cell proliferation status by detecting the activity of dehydrogenases within cells. Cell proliferation in hair follicles, especially the proliferation of hair follicle stem cells and hair matrix cells, is crucial for the regulation of the hair growth cycle and hair regeneration. Promoting the cell proliferation levels shown by the CCK-8 assay helps maintain hair follicle development and proliferation, promotes cellular mechanisms of hair growth, and thus promotes healthy hair follicles.

[0055] Vascular Endothelial Growth Factor (VEGF): VEGF is a key growth factor that plays an important role in angiogenesis and the proliferation of vascular endothelial cells. In the pathological process of hair loss, the microvascular network of hair follicles may be affected, leading to insufficient nutrient supply to the hair follicles. VEGF helps maintain the blood supply to the hair follicles and improves the symptoms of hair loss. Increasing the level of VEGF mentioned above refers to increasing the secretion level of VEGF or upregulating its expression.

[0056] Androgen receptor (AR) plays a crucial role in the mechanism of androgenetic alopecia (AGA). When androgens (such as DHT) bind to their receptor AR, hair follicles shrink, shortening the hair growth cycle and leading to hair loss. This application aims to reduce AR levels, including decreasing AR activity or downregulating AR protein expression, thereby reducing the impact of androgens on hair follicles, slowing down or preventing follicle shrinkage, and effectively preventing and treating hair loss.

[0057] Cytokines IL-6, IL-1, and TGF-β1: IL-6, IL-1, and TGF-β1 are key cytokines involved in inflammatory responses and cell signaling. High levels of IL-6 and IL-1 are associated with chronic inflammation, a significant factor contributing to hair loss. TGF-β1 normally helps stabilize the telogen phase of hair follicles, but abnormally elevated levels, especially in the hair follicle microenvironment, may inhibit the activity of hair follicle stem cells, prolong the telogen phase, and reduce hair growth. By reducing the secretion of these cytokines, the herbal composition of this application helps reduce scalp inflammation, alleviate abnormal signaling in the hair follicle microenvironment, activate hair follicle stem cells, and promote the growth of healthy hair. Lowering the levels of IL-6, IL-1, and TGF-β1 means reducing the secretion of IL-6, IL-1, and TGF-β1.

[0058] The regulation of the aforementioned biomarkers, regulatory factors, and protein indicators is a key biological basis for preventing hair loss, promoting hair follicle vitality, and fostering healthy hair growth. The traditional Chinese medicine composition of this application can precisely regulate the balance between hair follicle cell proliferation and apoptosis, inhibit DHT production, activate the β-catenin signaling pathway, inhibit GSK3β, promote cell proliferation, increase VEGF secretion levels, reduce androgen receptor levels, and reduce the secretion of inflammation-related cytokines. This traditional Chinese medicine composition can act on the scalp and hair follicles from multiple angles and levels, providing a comprehensive, long-lasting treatment plan with no significant side effects.

[0059] Ki67, as a marker of cell proliferation, promotes the proliferation of hair follicle stem cells by increasing its expression level, providing an adequate source of cells for new hair growth. Inhibiting Tunel expression effectively suppresses apoptosis, prolongs the hair follicle growth cycle, and maintains hair growth stability. DHT inhibition reduces the inducing factors of androgenetic alopecia, while the regulation of β-catenin and GSK3β provides a favorable environment for the activation of hair follicle stem cells. Promoting cell proliferation, increasing VEGF secretion to improve scalp blood circulation, reducing androgen receptor (AR) levels to decrease the impact of androgens on hair follicles, and reducing the secretion of inflammation-related cytokines all strengthen the structure and stability of hair follicles, providing a solid foundation for healthy hair growth.

[0060] When the traditional Chinese medicine composition of this application is applied to the preparation of drugs for preventing hair loss and promoting hair growth, compared with existing products for preventing hair loss and promoting hair growth, the traditional Chinese medicine composition of this application, due to the multi-target characteristics of traditional Chinese medicine, can promote the regeneration of hair follicle stem cells and enhance the structure of hair follicles and skin by upregulating the expression of Ki67 and β-catenin and downregulating the activity of Tunel, DHT, and GSK3β. Furthermore, because the traditional Chinese medicine composition also has mild properties, it avoids the potential side effects of the aforementioned chemically synthesized drugs, thus gently, safely, and effectively improving hair loss symptoms, providing strong technical support for the treatment of androgenetic alopecia (AGA).

[0061] In a preferred embodiment, the dosage form of the product includes an oral preparation; preferably, the oral preparation includes granules, tablets, capsules, solid beverages, or oral liquids.

[0062] In a second typical embodiment of this application, an application of the above-mentioned traditional Chinese medicine composition in the preparation of a product that increases hair follicle thickness is provided; the traditional Chinese medicine composition includes wolfberry, jujube, poria cocos, coix seed, longan pulp, mulberry and lotus seed. The aforementioned traditional Chinese medicine composition comprises 1-5 parts of Poria cocos, 0.5-3 parts of Lycium barbarum, 0.5-3 parts of Morus alba, 0.5-3 parts of Longan aril, 0.01-2 parts of Coix lacryma-jobi, 0.01-2 parts of Nelumbo nucifera, and 0.01-2 parts of Ziziphus jujuba. Preferably, by weight, the traditional Chinese medicine composition comprises 2-4 parts of Auricularia auricula-judae, 1-3 parts of Poria cocos, 1-3 parts of Lycium barbarum, 1-3 parts of Morus alba, 0.5-2 parts of Longan aril, 0.05-0.2 parts of Coix lacryma-jobi, 0.05-2 parts of Nelumbo nucifera, and 0.05-2 parts of Ziziphus jujuba. Preferably, the traditional Chinese medicine composition comprises Lycium barbarum, Ziziphus jujuba, Poria cocos, Coix lacryma-jobi, and Longan aril. The ingredients are: mulberry, black fungus, and lotus seeds; preferably, by weight, the traditional Chinese medicine composition includes 0.5-4 parts black fungus, 1-5 parts poria cocos, 0.5-3 parts wolfberry, 0.5-3 parts mulberry, 0.5-3 parts longan pulp, 0.01-2 parts coix seed, 0.01-2 parts lotus seed, and 0.01-2 parts jujube; preferably, by weight, the traditional Chinese medicine composition includes 2-4 parts black fungus, 1-3 parts poria cocos, 1-3 parts wolfberry, 1-3 parts mulberry, 0.5-2 parts longan pulp, 0.05-0.2 parts coix seed, 0.05-2 parts lotus seed, and 0.05-2 parts jujube.

[0063] In a third typical embodiment of this application, an application of a traditional Chinese medicine composition in the preparation of a product that increases skin thickness is provided; the traditional Chinese medicine composition includes wolfberry, jujube, poria cocos, coix seed, longan pulp, mulberry, and lotus seed. The aforementioned traditional Chinese medicine composition comprises 1-5 parts of Poria cocos, 0.5-3 parts of Lycium barbarum, 0.5-3 parts of Morus alba, 0.5-3 parts of Longan aril, 0.01-2 parts of Coix lacryma-jobi, 0.01-2 parts of Nelumbo nucifera, and 0.01-2 parts of Ziziphus jujuba. Preferably, by weight, the traditional Chinese medicine composition comprises 2-4 parts of Auricularia auricula-judae, 1-3 parts of Poria cocos, 1-3 parts of Lycium barbarum, 1-3 parts of Morus alba, 0.5-2 parts of Longan aril, 0.05-0.2 parts of Coix lacryma-jobi, 0.05-2 parts of Nelumbo nucifera, and 0.05-2 parts of Ziziphus jujuba. Preferably, the traditional Chinese medicine composition comprises Lycium barbarum, Ziziphus jujuba, Poria cocos, Coix lacryma-jobi, and Longan aril. The ingredients are: mulberry, black fungus, and lotus seeds; preferably, by weight, the traditional Chinese medicine composition includes 0.5-4 parts black fungus, 1-5 parts poria cocos, 0.5-3 parts wolfberry, 0.5-3 parts mulberry, 0.5-3 parts longan pulp, 0.01-2 parts coix seed, 0.01-2 parts lotus seed, and 0.01-2 parts jujube; preferably, by weight, the traditional Chinese medicine composition includes 2-4 parts black fungus, 1-3 parts poria cocos, 1-3 parts wolfberry, 1-3 parts mulberry, 0.5-2 parts longan pulp, 0.05-0.2 parts coix seed, 0.05-2 parts lotus seed, and 0.05-2 parts jujube.

[0064] In a fourth typical embodiment of this application, an application of a traditional Chinese medicine composition in the preparation of a product that promotes hair growth is provided; the traditional Chinese medicine composition includes wolfberry, jujube, poria cocos, coix seed, longan pulp, mulberry, and lotus seed. The aforementioned traditional Chinese medicine composition comprises 1-5 parts of Poria cocos, 0.5-3 parts of Lycium barbarum, 0.5-3 parts of Morus alba, 0.5-3 parts of Longan aril, 0.01-2 parts of Coix lacryma-jobi, 0.01-2 parts of Nelumbo nucifera, and 0.01-2 parts of Ziziphus jujuba. Preferably, by weight, the traditional Chinese medicine composition comprises 2-4 parts of Auricularia auricula-judae, 1-3 parts of Poria cocos, 1-3 parts of Lycium barbarum, 1-3 parts of Morus alba, 0.5-2 parts of Longan aril, 0.05-0.2 parts of Coix lacryma-jobi, 0.05-2 parts of Nelumbo nucifera, and 0.05-2 parts of Ziziphus jujuba. Preferably, the traditional Chinese medicine composition comprises Lycium barbarum, Ziziphus jujuba, Poria cocos, Coix lacryma-jobi, and Longan aril. The ingredients are: mulberry, black fungus, and lotus seeds; preferably, by weight, the traditional Chinese medicine composition includes 0.5-4 parts black fungus, 1-5 parts poria cocos, 0.5-3 parts wolfberry, 0.5-3 parts mulberry, 0.5-3 parts longan pulp, 0.01-2 parts coix seed, 0.01-2 parts lotus seed, and 0.01-2 parts jujube; preferably, by weight, the traditional Chinese medicine composition includes 2-4 parts black fungus, 1-3 parts poria cocos, 1-3 parts wolfberry, 1-3 parts mulberry, 0.5-2 parts longan pulp, 0.05-0.2 parts coix seed, 0.05-2 parts lotus seed, and 0.05-2 parts jujube.

[0065] In a fifth typical embodiment of this application, an application of a composition in the preparation of a product for improving hair loss is provided. The composition comprises composition A and composition B; wherein composition A comprises wolfberry, jujube, poria cocos, coix seed, longan pulp, mulberry, and lotus seed; composition B comprises one or more of the following: arborvitae leaf, fleeceflower root, anemarrhena rhizome, eclipta prostrata, sophora flavescens root, saposhnikovia root, phellodendron bark, rehmannia root, or flaxseed; by weight, composition A comprises one or more of the following: 1-5 parts poria cocos, 0.5-3 parts wolfberry, 0.5-3 parts mulberry, 0.5-2 parts longan pulp, 0.05-2 parts coix seed, 0.05-2 parts lotus seed, and 0.05-2 parts jujube. Preferably, composition A includes wolfberry, jujube, poria cocos, coix seed, longan pulp, mulberry, black fungus, and lotus seed; preferably, by weight, composition A includes 0.5-4 parts black fungus, 1-5 parts poria cocos, 0.5-3 parts wolfberry, 0.5-3 parts mulberry, 0.5-3 parts longan pulp, 0.01-2 parts coix seed, 0.01-2 parts lotus seed, and 0.01-2 parts jujube; preferably, by weight, composition A includes 2-4 parts black fungus, 1-3 parts poria cocos, 1-3 parts wolfberry, 1-3 parts mulberry, 0.5-2 parts longan pulp, 0.05-0.2 parts coix seed, 0.05-2 parts lotus seed, and 0.05-2 parts jujube.

[0066] In a preferred embodiment, the above composition B includes Platycladus orientalis leaves, Polygonum multiflorum, Anemarrhena asphodeloides, Eclipta prostrata, Sophora flavescens, Saposhnikovia divaricata, Phellodendron chinense, Rehmannia glutinosa, and flaxseed; preferably, the above composition B includes 0.1-3 parts of Platycladus orientalis leaves, 0.1-2.5 parts of Polygonum multiflorum, 0.05-2 parts of Anemarrhena asphodeloides, 0.01-0.15 parts of Eclipta prostrata, 0.005-0.1 parts of Sophora flavescens, 0.01-0.15 parts of Saposhnikovia divaricata, 0.01-0.15 parts of Phellodendron chinense, 0.01-0.2 parts of Rehmannia glutinosa, and 0.001-1 parts of flaxseed.

[0067] In a sixth typical embodiment of this application, a product for improving hair loss is provided, the raw material of which is the above-mentioned traditional Chinese medicine composition; preferably, the product also includes a pharmaceutically acceptable carrier.

[0068] Pharmaceutically acceptable carriers include, but are not limited to, one or more of solvents, matrices, emulsifiers, binders, fillers, surfactants, excipients, or solubilizers.

[0069] The term "improvement of hair loss" in this application includes, but is not limited to, increasing one or more of the following indicators: hair quantity, hair length, hair follicle width, or scalp skin thickness; preferably, improving hair loss includes regulating one or more of the following indicators: upregulating the expression of cell proliferation-promoting factors, downregulating cell apoptosis levels, downregulating dihydrotestosterone secretion levels, upregulating β-catenin expression, downregulating glycogen synthesis kinase 3β expression, promoting cell proliferation (CCK-8 assay), increasing vascular endothelial growth factor (VEGF) levels, decreasing androgen receptor levels, and decreasing inflammatory factor levels; preferably, inflammatory factors include one or more of interleukin-1, interleukin-6, or TGF-β1. The levels of IL-6, IL-1, and TGF-β1 are also considered. Unless otherwise specified, all reagents used in the embodiments of this application are conventional commercially available products.

[0070] The beneficial effects of this application will be explained in more detail below with reference to specific embodiments.

[0071] Example 1

[0072] The traditional Chinese medicine composition in this embodiment includes 2 parts of wolfberry, 0.05 parts of jujube, 2 parts of poria cocos, 0.1 parts of coix seed, 2 parts of longan pulp, 2 parts of mulberry, 2 parts of black fungus and 0.05 parts of lotus seed.

[0073] Methods for preparing oral liquid include:

[0074] Extraction 1: Add Job's tears, lotus seeds, jujubes, black fungus, and Poria cocos. For the first extraction, add 20 times the total amount of drinking water of the above-mentioned Chinese herbs, bring to a boil, and maintain boiling for 2 hours. For the second extraction, add 20 times the total amount of drinking water of the Chinese herbs, bring to a boil, and maintain boiling for 1.5 hours. Filter the extract through an 80-mesh sieve.

[0075] Extraction 2: Add wolfberry, longan pulp, and mulberry. For the first extraction, add 10 times the total amount of drinking water of the above-mentioned Chinese medicinal materials, bring to a boil, and maintain boiling for 2 hours. For the second extraction, add 10 times the total amount of drinking water of the Chinese medicinal materials, bring to a boil, and maintain boiling for 1.5 hours. Filter the extract through an 80-mesh sieve. Combine and concentrate the first and second extractions to obtain a concentrated Chinese medicinal liquid.

[0076] The concentrated Chinese medicine liquid and 3wt% soybean peptides are added to the mixing tank and stirred to dissolve. After centrifugation, filtration and sterilization, the oral liquid is obtained.

[0077] Example 2

[0078] The traditional Chinese medicine composition of this embodiment includes 3 parts of wolfberry, 0.2 parts of jujube, 1 part of poria cocos, 0.05 parts of coix seed, 0.5 parts of longan pulp, 1 part of mulberry, 2 parts of black fungus and 0.05 parts of lotus seed.

[0079] The preparation method is the same as in Example 1.

[0080] Example 3

[0081] The traditional Chinese medicine composition in this embodiment includes 1 part wolfberry, 0.2 part jujube, 3 parts poria cocos, 0.2 part coix seed, 2 parts longan pulp, 3 parts mulberry, 4 parts black fungus and 0.2 parts lotus seed.

[0082] The method for preparing the oral liquid is the same as in Example 1.

[0083] Example 4

[0084] The traditional Chinese medicine composition of this embodiment includes 0.5 parts of wolfberry, 2 parts of jujube, 5 parts of poria cocos, 0.01 parts of coix seed, 0.5 parts of longan pulp, 3 parts of mulberry, 0.5 parts of black fungus and 0.01 parts of lotus seed.

[0085] The method for preparing the oral liquid is the same as in Example 1.

[0086] Example 5

[0087] The traditional Chinese medicine composition in this embodiment includes 3 parts of wolfberry, 0.01 parts of jujube, 1 part of poria cocos, 2 parts of coix seed, 3 parts of longan pulp, 0.5 parts of mulberry, 4 parts of black fungus, and 2 parts of lotus seed.

[0088] The method for preparing the oral liquid is the same as in Example 1.

[0089] Example 6 The traditional Chinese medicine composition of this example includes 2 parts of wolfberry, 0.05 parts of jujube, 2 parts of poria cocos, 0.1 parts of coix seed, 2 parts of longan pulp, 2 parts of mulberry and 0.05 parts of lotus seed.

[0090] The method for preparing the oral liquid is the same as in Example 1.

[0091] Comparative Example 1

[0092] The traditional Chinese medicine composition in this comparative example includes 2 parts of wolfberry, 0.05 parts of jujube, 2 parts of black fungus, 0.1 parts of coix seed, 2 parts of longan pulp, 2 parts of mulberry, and 0.05 parts of lotus seed.

[0093] The method for preparing the oral liquid is the same as in Example 1.

[0094] Comparative Example 2

[0095] The traditional Chinese medicine composition in this comparative example includes 2 parts of black fungus, 0.05 parts of jujube, 2 parts of poria cocos, 0.1 parts of coix seed, 2 parts of longan pulp, 2 parts of mulberry, and 0.05 parts of lotus seed.

[0096] The method for preparing the oral liquid is the same as in Example 1.

[0097] Comparative Example 3

[0098] The traditional Chinese medicine composition in this comparative example includes 2 parts of wolfberry, 0.05 parts of jujube, 2 parts of poria cocos, 0.1 parts of coix seed, 2 parts of longan pulp, 2 parts of black fungus, and 0.05 parts of lotus seed.

[0099] The method for preparing the oral liquid is the same as in Example 1.

[0100] Comparative Example 4

[0101] The traditional Chinese medicine composition in this comparative example includes 2 parts of wolfberry, 0.05 parts of jujube, 2 parts of poria cocos, 0.1 parts of coix seed, 2 parts of black fungus, 2 parts of mulberry, and 0.05 parts of lotus seed.

[0102] The method for preparing the oral liquid is the same as in Example 1.

[0103] Comparative Example 5

[0104] The traditional Chinese medicine composition in this comparative example includes 2 parts of wolfberry, 2 parts of mulberry, and 2 parts of longan pulp.

[0105] The method for preparing the oral liquid is the same as in Example 1.

[0106] Comparative Example 6

[0107] The traditional Chinese medicine composition in this comparative example includes 2 parts of wolfberry, 2 parts of mulberry, 2 parts of longan pulp, and 0.05 parts of jujube.

[0108] The method for preparing the oral liquid is the same as in Example 1.

[0109] Comparative Example 7

[0110] The traditional Chinese medicine composition in this comparative example includes 1 part of wolfberry.

[0111] The method for preparing the oral liquid is the same as the extraction step 2 in Example 1.

[0112] Comparative Example 8

[0113] The traditional Chinese medicine composition in this comparative example includes 1 part mulberry.

[0114] The method for preparing the oral liquid is the same as the extraction step 2 in Example 1.

[0115] Comparative Example 9

[0116] The traditional Chinese medicine composition in this comparative example includes 1 part of longan pulp.

[0117] The method for preparing the oral liquid is the same as the extraction step 2 in Example 1.

[0118] Comparative Example 10

[0119] The traditional Chinese medicine composition in this comparative example includes 1 part of Poria cocos.

[0120] The method for preparing the oral liquid is the same as the extraction step in Example 1.

[0121] Comparative Example 11

[0122] The traditional Chinese medicine composition in this comparative example includes 1 part of black fungus.

[0123] The method for preparing the oral liquid is the same as the extraction step in Example 1.

[0124] Test Example 1

[0125] The test groups are as follows:

[0126] Normal group: Blank control group.

[0127] Model group: AGA animal model and cell model were constructed using DHT (dihydrotestosterone).

[0128] Both the sample group and the control group used DHT-induced animal and cell models and were respectively administered the traditional Chinese medicine compositions from the above examples and comparative examples.

[0129] Among them, sample groups 1 to 5 are groups that use the traditional Chinese medicine compositions of Examples 1 to 5 for testing, and control groups 1 to 12 are groups that use the traditional Chinese medicine compositions of Comparative Examples 1 to 12 for testing.

[0130] 1) Morphological examination:

[0131] Five-week-old male C57 / BL6 mice were purchased and, after one week of acclimatization, were randomly divided into a normal group, a model group, a positive control group (5% minoxidil), a sample group, and a topical preparation + oral sample group.

[0132] An AGA model was established using male C57 / BL6 mice after hair removal and subcutaneous injection of DHT.

[0133] The normal group was injected with 200 μL of normal saline every 2 days, and DHT was not used to establish the model.

[0134] The model group was injected with 200 μL of DHT solution (0.5 mg / mL) every 2 days.

[0135] Sample groups 1-5 were injected with 200 μL of DHT solution (0.5 mg / mL) every 2 days, and at the same time, they were given 15 mL / Kg / bW / day of the traditional Chinese medicine composition of Examples 1-5 by gavage.

[0136] Control groups 1-12 were injected with 200 μL of DHT solution (0.5 mg / mL) every 2 days, and at the same time, they were given 15 mL / Kg / bW / day of the corresponding Chinese medicine composition by gavage.

[0137] The sample group was injected with 200 μL of DHT solution (0.5 mg / mL) every 2 days, and 0.3 mL of the topical preparation was applied to the sample every day. The sample group was also given 15 mL / Kg / bW / day of the traditional Chinese medicine composition of Example 1 by gavage. The modeling and treatment continued for 20 days.

[0138] The above-mentioned topical preparation is Zhiya Hair Strengthening and Anti-Hair Loss Essence, National Cosmetic Special Approval Number 20232928 (the raw material Chinese herbal composition includes 0.1-3 parts of Platycladus orientalis leaf, 0.1-2.5 parts of Polygonum multiflorum, 0.05-2 parts of Anemarrhena asphodeloides, 0.01-0.15 parts of Eclipta prostrata, 0.005-0.1 parts of Sophora flavescens, 0.01-0.15 parts of Saposhnikovia divaricata, 0.01-0.15 parts of Phellodendron chinense, 0.01-0.2 parts of Rehmannia glutinosa and 0.001-1 parts of flaxseed).

[0139] During the treatment, the condition of the mouse's back skin and hair growth were observed and photographed. After treatment, each group of mice was sacrificed to obtain skin tissue and blood for testing relevant indicators.

[0140] The specific experimental data are as follows:

[0141] ① Tissue sections of the skin on the back of mice were prepared and stained with hematoxylin and eosin (HE). The hair follicles and skin conditions of mice in the normal group, model group, minoxidil group, sample group, and sample + topical preparation group were observed, photographed, and analyzed.

[0142] Images of morphological experiments, such as Figure 1 As shown.

[0143] Depend on Figure 1 It is evident that the hair follicles in the model group are in a state of atrophy and miniaturization, with thin skin and no hair growth.

[0144] The sample group was able to significantly increase hair follicle width and increase skin thickness.

[0145] Data statistics and analysis were performed on hair follicle width and skin thickness, specifically as follows: Figure 2 and Figure 3 As shown, the results indicate that, compared to the model group, the sample group significantly increased hair follicle width and improved skin thickness. Sample group 1 showed the best results.

[0146] The hair follicles and skin condition in the control group were far worse than those in the sample group.

[0147] Based on the above morphological images and experimental data, the traditional Chinese medicine composition of this application can improve the condition of hair follicles and skin, and promote hair growth.

[0148] ② Observe the morphological changes in the skin and hair growth of mice:

[0149] Detection method:

[0150] Results: Normal (NC) mice had smooth, shiny skin, and by day 14, the back area of ​​the mice was basically covered with hair, showing a typical natural recovery pattern. Compared with the normal group, hair growth in the model group was slow, indicating a significant inhibitory effect on hair growth after dihydrotestosterone (DHT) treatment, demonstrating the successful establishment of the AGA model. The minoxidil group significantly improved the hair growth inhibition caused by DHT, showing good hair growth by day 14 compared to the model group, demonstrating significant promotion of hair regeneration as a clinical treatment for hair loss. The example group significantly promoted hair regeneration compared to the model group, indicating that it improved the hair growth inhibition caused by DHT. Figure 4 As shown.

[0151] Compared with the model group, the sample group had more hair, faster hair growth rate, and longer average hair length. Among them, sample group 1 showed the best results. In the control group, the improvement in hair quantity and average hair length was not significant compared with the model group.

[0152] 2) The results of the immunofluorescence assay are as follows:

[0153] The testing methods for Ki67 and Tunel were as follows: Skin tissue from the back of mice was taken from step 1) above, and the specimen was fixed in 4% paraformaldehyde solution to prepare paraffin sections. After dewaxing the paraffin sections to water, they were incubated with primary antibody solution, secondary antibody solution, and DAPI solution in sequence, and then dehydrated and mounted. Images were acquired using a fluorescence microscope to obtain the results of immunofluorescence Ki67 and Tunel.

[0154] ①Ki67: Experimental results showed that all sample groups could significantly increase Ki67 expression, promote cell proliferation, and promote hair growth. The combined oral and topical preparations had a synergistic effect, and the improvement effect of the control group was worse than that of the sample group.

[0155] The statistical graph of the positive rate of Ki67 staining in skin tissue is shown below. Figure 5 As shown. The unit of the vertical axis is "%".

[0156] ②Tunel positivity rate: All sample groups showed significant downregulation of Tunel expression, which in turn downregulates apoptosis. The effect of downregulating apoptosis was even better when combined with topical application. The control groups showed poorer downregulation effects than the sample groups.

[0157] Statistical graph of skin tissue tuber positivity rate as shown in the figure. Figure 6 As shown. The unit of the vertical axis is "%".

[0158] 3) DHT:

[0159] DHT (dihydrotestosterone) test method: After the mouse experiment in 1) above, the mice were enucleated to obtain blood and the mouse serum was stored in a -80℃ freezer. The DHT level in the mouse serum was detected using an ELISA kit (Inova (Wuhan) Technology Co., Ltd.).

[0160] Experimental data showed that all sample groups significantly reduced DHT levels, and the effect of combining with topical formulations was slightly better than that of the sample groups in lowering DHT levels. The control groups showed significantly worse improvement than the sample groups.

[0161] Statistical results of DHT (dihydrotestosterone) secretion levels are as follows: Figure 7 As shown.

[0162] 4) Western blot analysis was used to test β-catenin and GSK3β in the tissues from step 1). Total cellular protein and nucleoprotein were extracted according to the kit instructions (Wuhan Sewell Biotechnology Co., Ltd.), followed by SDS-PAGE electrophoresis, transfection, blocking, antibody incubation, development, and data analysis. The mouse modeling and processing methods used here were the same as those used in step 1).

[0163] β-catenin:

[0164] The experimental results are as follows: All sample groups significantly increased β-catenin levels and enhanced hair follicle stem cell vitality. Furthermore, the combined internal-external conditioning and external nourishment group showed a significantly better effect on increasing β-catenin levels than the sample groups, demonstrating a synergistic effect in enhancing hair follicle stem cell activity. The control groups showed significantly worse improvement than the sample groups.

[0165] The statistical results of β-catenin expression level in this embodiment are as follows: Figure 8 As shown, the vertical axis “β-catenin (ratio)” refers to the expression level of β-catenin.

[0166] GSK3β:

[0167] Experimental results showed that all sample groups significantly downregulated GSK3β, and the combined internal-external regulation and external nourishment group showed a significantly better downregulation effect on GSK3β than the sample groups, exhibiting a synergistic effect and promoting the activation and proliferation of hair follicle stem cells. The control groups showed significantly worse improvement than the sample groups.

[0168] The statistical results of GSK3β expression level in this embodiment are as follows: Figure 9 As shown, the vertical axis “GSK3β (ratio)” refers to the expression level of GSK3β.

[0169] 5) CCK-8 cell proliferation test, detection of vascular endothelial growth factor (VEGF), detection of androgen receptor levels, and detection of IL-6, IL-1 and TGF-β1.

[0170] In multiple testing experiments, the sample + topical preparation group had the best indicators, and both the sample + topical preparation group and the sample group obtained positive results; the above indicators of the sample group were better than those of the control group.

[0171] Furthermore, this embodiment selected 9 specific groups of samples for testing, and the steps and results are as follows:

[0172] 5.1.1 Cells were treated with samples at different concentration gradients to investigate the safe concentration range (cytotoxicity assessment) of nine test samples (Group A corresponds to the composition of Example 1; Group B corresponds to the composition of Example 4; Group C corresponds to the composition of Example 2; Group D corresponds to the composition of Example 6; Group E corresponds to the composition of Comparative Example 1; Group F corresponds to the composition of Comparative Example 3; Group G corresponds to the composition of Comparative Example 4; Group H corresponds to Comparative Example 5; Group I corresponds to Comparative Example 6; hereinafter, the descriptions are omitted as A, B, C, D, E, F, G, H, AI) in human dermal papilla cells (HDPCS).

[0173] 5.1.2 Investigate the repair effects of nine test samples (AI) on a dihydrotestosterone (DHT)-induced human dermal papilla cell (HDPCS) damage model (cell proliferation assay).

[0174] 5.1.3 Investigate the effects of nine test samples (AI) on relevant indicators in a dihydrotestosterone (DHT)-induced human dermal papilla cell (HDPCS) injury model (interleukin-6 (IL-6), androgen receptor (AR), vascular endothelial growth factor (VEGF), human β-catenin, human transforming growth factor β1 (TGF-β1), and human fibroblast growth factor 7 (FGF7).

[0175] 5.2 Experimental Materials

[0176] The material information used in the testing is shown in Table 1.

[0177] Table 1

[0178]

[0179] 5.3.1 All nine samples were 100% concentrated, diluted to 10% with PBS, filtered through a 0.22 μm filter membrane, and stored at 4°C for later use. Before the experiment, they were diluted to the corresponding concentrations with complete culture medium. The 10% concentration samples after filtration could be stored at 4°C for 2 weeks, and the 100% concentration samples could be stored at 4°C for 4 weeks.

[0180] 5.3.2 Cytotoxicity testing of active ingredients

[0181] 1. Take HDPCS cells in the logarithmic growth phase and distribute them at 2 × 10⁶ cells per well. 4 Cells were seeded at the specified density in 96-well plates, with 200 μL of complete culture medium added to each well, and incubated for 24 h.

[0182] 2. After incubation, add 200 μL of samples diluted to different concentrations with complete culture medium to each well and incubate for 72 h.

[0183] 3. After incubation, aspirate the old culture medium and add 200 μL of medium containing 10% CCK8. Incubate at 37℃ for 0–4 h. Measure the absorbance at 450 nm using a microplate reader and calculate the cell viability. The formula for calculating cell viability is as follows:

[0184] .

[0185] Note: OD0 represents the absorbance value of the normal group (containing cells, culture medium, and CCK-8 solution, but without drugs and without modeling), ODA represents the absorbance value of the sample group (model group and positive drug group), and ODB represents the absorbance value of the blank group (containing culture medium and CCK-8 solution, but without cells, drugs, and without modeling).

[0186] 5.3.3 Constructing a dihydrotestosterone (DHT)-induced damage model

[0187] 1. Take HDPCS cells in the logarithmic growth phase and distribute them at 2 × 10⁶ cells per well. 4 Cells were seeded at the specified density in 96-well plates, with 200 μL of complete culture medium added to each well, and incubated for 24 h.

[0188] 2. After incubation, add 200 μL of dihydrotestosterone (DHT) diluted to different concentrations with complete culture medium and incubate for 48 h.

[0189] 3. After incubation, aspirate the old culture medium and add 200 μL of medium containing 10% CCK8. Incubate at 37℃ for 0–4 h. Measure the absorbance at 450 nm using a microplate reader and calculate the cell viability. The formula for calculating cell viability is as follows:

[0190] .

[0191] Note: OD0 represents the absorbance value of the normal group (containing cells, culture medium, and CCK-8 solution, but without drugs and without modeling), ODA represents the absorbance value of the sample group (model group and positive drug group), and ODB represents the absorbance value of the blank group (containing culture medium and CCK-8 solution, but without cells, drugs, and without modeling).

[0192] 5.3.4 Effects of the sample on dihydrotestosterone (DHT)-induced HDPCS cell viability

[0193] 1. Take HDPCS cells in the logarithmic growth phase and distribute them at 2 × 10⁶ cells per well. 4 Cells were seeded at the specified density in 96-well plates, with 200 μL of complete culture medium added to each well, and incubated for 24 h.

[0194] 2. After incubation, add 200 μL of sample diluted to different concentrations with complete culture medium to each well, place in a cell culture incubator, and pre-protect for 24 h.

[0195] 3. After incubation, discard the culture medium and add samples diluted to different concentrations with complete culture medium and 10 μM DHT, 200 μL per well. The model group is added only with 10 μM DHT complete culture medium, and the normal group is added only with complete culture medium. Place in a cell culture incubator and continue incubation for 48 h.

[0196] 4. After incubation, aspirate the old culture medium and add 200 μL of medium containing 10% CCK8. Incubate at 37℃ for 0–4 h. Measure the absorbance at 450 nm using a microplate reader. The calculation formula is as follows:

[0197] The formula for calculating cell viability is as follows:

[0198] ;

[0199] Note: OD sample represents the absorbance value of the sample group, OD blank represents the absorbance value of the blank group (containing culture medium and CCK-8 solution, but without cells, drugs, or modeling), and OD normal represents the absorbance value of the normal group (containing cells, culture medium, and CCK-8 solution, but without drugs or modeling).

[0200] The formula for calculating the repair capacity of a sample is as follows:

[0201] ;

[0202] Note: Cell viability sample represents the cell viability value of the sample group, and cell viability model represents the cell viability value of the model group.

[0203] 5.3.5 Effects of the sample on relevant indicators of dihydrotestosterone (DHT)-induced HDPCS cells

[0204] 1. Cell seeding: HDPCS cells in the logarithmic growth phase were seeded at a concentration of 1 × 10⁻⁶ cells / mL. 5 Cells were seeded at a density of 2 mL / mL in 6-well plates and incubated for 24 h.

[0205] 2. Cell pre-protection: After incubation, add samples diluted to different concentrations with complete culture medium and continue incubation for 24 h.

[0206] 3. After incubation, remove the old culture medium and add 2 ml of complete culture medium containing 10 μM dihydrotestosterone and different concentrations of samples (the model group only added 10 μM DHT complete culture medium, and the normal group only added complete culture medium) to each well, mix well and incubate for 48 h.

[0207] 4. Cell collection: After incubation, collect the supernatant, wash the cells twice with PBS, add 500 μL / well trypsin for digestion, and incubate for 1 min.

[0208] 5. Observe the cells under a microscope. Once the cells have detached in large flakes, immediately add 1.5 mL of complete culture medium to stop digestion.

[0209] 6. Pipe the cells and collect them into a 2 mL ep tube, centrifuge at 1000 rpm for 10 minutes at 4°C.

[0210] 7. Wash the cells twice, discard the culture medium, add 1 mL of PBS, pipette the cells to suspend them evenly, centrifuge at 1000 rpm for 10 minutes at 4°C.

[0211] 8. Complete the test according to the operating instructions (instructions) of the ELISA kit.

[0212] The indicators that need to be tested are as follows:

[0213] The following indicators were detected in the nine samples: interleukin-6 (IL-6), androgen receptor (AR), vascular endothelial growth factor (VEGF), and human catechol β1 (β-catenin).

[0214] The indicators of seven samples were detected: human transforming growth factor β1 (TGF-β1) and human fibroblast growth factor 7 (FGF).

[0215] 5.4.1 Cytotoxicity Results and Analysis of Active Ingredients

[0216] The effect of some active ingredients on HDPCS cell viability was detected by the CCK8 assay. Cell viability > 85% was considered to be non-cytotoxic. The results are shown in Table 2.

[0217] At concentrations of 1% and 5%, the cell viability of all nine samples was below 85%, indicating significant cytotoxicity.

[0218] Samples A, G, and H, at a concentration of 0.5%, showed cell viability below 85% and significant cytotoxicity.

[0219] Samples C, E, F, and I exhibited cell viability above 85% at a concentration of 0.5%, but microscopic observation revealed a decrease in cell number and altered cell morphology, indicating cytotoxicity at this concentration. Microscopic images are shown below. Figure 10 As shown in the image. Because the culture medium is colored at a sample concentration of 0.5%, the absorbance of the light-sensitive material increases. Subsequent experiments used samples with concentrations below 0.5%.

[0220] Table 2. Cytotoxicity results of active ingredients

[0221]

[0222] Note: The underlined data in Table 2 indicate that the cells under those data points were cytotoxic (74% for sample A at 0.5% concentration, 49% for sample G at 0.5% concentration, 4% for sample H at 0.5% concentration, and data for 1% and 5% concentrations in all sample groups); false positive results include 86% for sample C at 0.5% concentration, 110% for sample E at 0.5% concentration, 96% for sample F at 0.5% concentration, and 90% for sample I at 0.5% concentration.

[0223] 5.4.2 Literature search for appropriate concentrations of positive drugs

[0224] Based on literature search, relevant information is shown in Table 3. The selected positive drug concentration for subsequent experiments was minoxidil (2 μg / mL).

[0225] Table 3 Positive drug concentration

[0226]

[0227] 5.4.3 Constructing a dihydrotestosterone (DHT)-induced damage model

[0228] The effects of some active ingredients on HDPCS cell viability were detected using the CCK8 assay, and the results are shown in Table 4. Cell viability > 85% was considered to indicate no cytotoxicity.

[0229] At 10 μM, DHT resulted in 88% cell viability and no cytotoxicity. Subsequent experiments used 10 μM DHT to induce damage in HDPCS cells.

[0230] Table 4 Results of DHT on HDPCS cell viability

[0231]

[0232] 5.4.4 Investigating the Effects of Samples on Cell Viability Based on an Oxidative Damage Cell Model

[0233] The effect of the samples on the viability of HDPCS cells induced by dihydrotestosterone was detected by the CCK8 assay. The cell viability of the sample group was compared with that of the model group (100%) to determine that there was no cell proliferation effect. The results are shown in Table 5.

[0234] Experiments showed that the model group was effective and the positive group was valid. All tested samples resisted DHT-induced cell damage, demonstrating its protective effect on hair follicle dermal cells. Experimental data showed that at a high concentration of 0.1%, compared to a concentration of 0.05%, cell viability decreased in all nine samples. In fact, the cell viability of groups A, C, E, and F was lower than that of the model group, indicating that these groups experienced synergistic damage after reacting with DHT, leading to decreased cell viability. Therefore, it is recommended to select a concentration <0.05% for future applications.

[0235] Table 5. Effects of samples on the viability of HDPCS cells after DHT induction (model group normalized)

[0236]

[0237] Note: The underlined data in Table 5 represent the cytotoxicity of cells at that data point (98% for sample A at 0.1% concentration, 88% for sample C at 0.1% concentration, and 89% for sample F at 0.1% concentration).

[0238] In the first experiment, we found that a sample concentration of 0.1% might synergistically damage cells after reacting with DHT, leading to decreased cell viability. To avoid the high concentration of 0.1% and further explore the effects at lower concentrations, we conducted supplementary experiments to further determine the effects of nine samples on the viability of DHT-induced HDPCS cells. The results are shown in Table 6.

[0239] The experimental results showed that all 10 samples had a repair effect on hair follicle dermal cells after DHT induction, and the repair effect was dose-dependent. Nine samples showed outstanding protective effects at a concentration of 0.05%. The repair effects of all groups are shown in Table 7.

[0240] Table 6. Effects of samples on the viability of HDPCS cells after DHT induction (normalized by model group)

[0241]

[0242] Table 7. Effects of samples on the repair of DHT-induced HDPCS cells (normal group normalized).

[0243]

[0244] 5.4.5 Effects of the sample on relevant indicators of dihydrotestosterone (DHT)-induced HDPCS cells

[0245] 5.4.5.1 Interleukin-6 (IL-6)

[0246] In this experiment, the anti-inflammatory efficacy of the samples was assessed by detecting the IL-6 inhibition rate in a DHT-induced HDPCS cell model. Data showed that the inhibition rate of DHT-induced IL-6 in the sample groups was significantly better than that in the model group at high concentrations. The results are shown in Table 8.

[0247] Table 8. Inhibition rate of DHT-induced inflammatory factor (IL-6) by the sample (compared with the model group)

[0248]

[0249] In Table 8, P<0.05 indicates a significant result; P<0.01 indicates a highly significant result; P<0.001 indicates a very significant result; and P<0.0001 indicates an extremely significant result.

[0250] 5.4.5.2 Androgen receptor (AR)

[0251] The effects of different concentrations of each composition on the relative expression level of androgen receptor AR in a DHT-damaged cell model were investigated to evaluate their anti-hair loss efficacy. A higher "inhibition rate" value indicates a better inhibitory effect on androgen receptor AR and a better anti-hair loss efficacy. Samples E, H, and I showed no significant inhibitory effect on androgen receptor AR at a low concentration of 0.005%. Other sample groups showed significantly better inhibition rates on androgen receptor AR-related indicators at both high and low concentrations compared to the model group. The results are shown in Table 9.

[0252] Table 9. Inhibition rate of the sample on the androgen receptor AR after DHT induction (compared with the model group)

[0253]

[0254] In Table 9, P<0.05 indicates a significant result; P<0.01 indicates a highly significant result; P<0.001 indicates a very significant result; and P<0.0001 indicates an extremely significant result.

[0255] 5.4.5.3 Vascular endothelial growth factor (VEGF)

[0256] In this experiment, the pro-angiogenic efficacy of samples was assessed by detecting the VEGF promotion rate in a DHT-induced HDPCS cell model. Data showed that most samples (except group H) exhibited significantly better VEGF promotion rates than the model group at both high and low concentrations. Sample A demonstrated excellent VEGF promotion effects, exceeding the promotion rates of other groups. The results are shown in Table 10.

[0257] Table 10. Promotion rate of vascular endothelial growth factor (VEGF) after DHT induction by the sample (compared with the model group)

[0258]

[0259] In Table 10, P<0.05 indicates a significant result; P<0.01 indicates a highly significant result; P<0.001 indicates a very significant result; and P<0.0001 indicates an extremely significant result.

[0260] 5.4.5.4 β-catenin

[0261] In this experiment, the activation effect of samples on the Wnt signaling pathway was evaluated by detecting the β-catenin promotion rate in a DHT-induced HDPCS cell model. Data showed that at a concentration of 0.05%, samples A, B, C, D, and F significantly promoted DHT-induced β-catenin activation compared to the model group, with sample A showing the best effect. Samples E, G, H, and I had no significant effect on the DHT-induced β-catenin activation rate. The results are shown in Table 11.

[0262] Table 11. Promotion rate of DHT-induced β-catenin by the samples (compared with the model group)

[0263]

[0264] In Table 11, P<0.05 indicates a significant result; P<0.01 indicates a highly significant result; P<0.001 indicates a very significant result; and P<0.0001 indicates an extremely significant result.

[0265] 5.4.5.5 Fibroblast growth factor 7 (FGF7)

[0266] In this experiment, the regulatory efficacy of samples on the hair follicle growth microenvironment was evaluated by detecting the FGF7 promotion rate in a DHT-induced HDPCS cell model. Data showed that samples A, B, C, D, E, and G all significantly improved the DHT-induced FGF7 promotion rate compared to the model group, with sample A showing the best performance. Samples H and I had no significant effect on the DHT-induced FGF7 promotion rate. The results are shown in Table 12.

[0267] Table 12. Promotion rate of fibroblast growth factor 7 (FGF7) after DHT induction by the sample (compared with the model group)

[0268]

[0269] In Table 12, P<0.05 indicates a significant result; P<0.01 indicates a highly significant result; P<0.001 indicates a very significant result; and P<0.0001 indicates an extremely significant result.

[0270] 5.4.5.6 Transforming growth factor β1 (TGF-β1)

[0271] In this experiment, using a DHT-induced HDPCS cell model, the regulatory efficacy of samples on the hair follicle inhibitory microenvironment was assessed by detecting the TGF-β1 inhibition rate. Data showed that samples H and I did not exhibit significant inhibitory effects, while all other samples showed significant TGF-β1 inhibition. Samples A and D showed strong TGF-β1 inhibitory effects. The results are shown in Table 13.

[0272] Table 13 Inhibition rate of DHT-induced transforming growth factor β1 (TGF-β1) in the sample (compared with the model group)

[0273]

[0274] In Table 13, P<0.05 indicates a significant result; P<0.01 indicates a highly significant result; P<0.001 indicates a very significant result; and P<0.0001 indicates an extremely significant result.

[0275] in conclusion:

[0276] Cytotoxicity results and analysis of the active ingredients: At concentrations of 1% and 5%, cell viability was below 85%, showing a sharp decline and significant cytotoxicity. Samples A, G, and H also showed significant cytotoxicity at a concentration of 0.5%, with cell viability below 85%. Samples C, E, F, G, and I showed cell viability above 85% at a concentration of 0.5%, but microscopic observation revealed a decrease in cell number and altered cell morphology, indicating cytotoxicity at this concentration; the increased cell viability was due to false positives. Subsequent experiments selected samples with concentrations below 0.5%.

[0277] Effects of samples on the viability of dihydrotestosterone (DHT)-induced HDPCS cells: Experimental results showed that all nine samples had the effect of proliferating and repairing DHT-induced hair follicle dermal cells.

[0278] The ability to promote proliferation and repair means that all samples in each group could provide nutrients to cells and promote cell proliferation and division. From a mechanistic perspective, preventing hair loss requires comprehensive consideration of mechanisms such as inhibiting inflammatory oxidative damage, activating the Wnt5a / β-catenin pathway, promoting growth regulators (FGF), and promoting blood circulation and metabolism (VEGF). Cell proliferation level cannot fully represent the efficacy level of hair loss prevention and is not necessarily correlated with hair loss efficacy indicators.

[0279] Therefore, based on a comprehensive analysis of the test results of the six indicators, samples A through D showed superior overall performance and relative stability. Sample A exhibited the best effect on most indicators (such as VEGF, β-catenin, FGF7, and TGF-β1), and also outperformed most sample groups in IL-6 and AR indicators.

[0280] As can be seen from the above description, the embodiments of the present invention achieve the following technical effects: The traditional Chinese medicine composition of this application, through the combination of wolfberry, jujube, poria cocos, coix seed, longan pulp, mulberry, black fungus, and lotus seed, exerts the efficacy of each component. The components work synergistically to improve the symptoms of androgenetic alopecia (AGA) from multiple dimensions and promote the regeneration and repair of healthy hair. The traditional Chinese medicine composition of this application can increase hair follicle width and skin thickness, enhance the expression of Ki67 cell proliferation factor, inhibit Tunel cell apoptosis factor, effectively reduce DHT levels, activate β-catenin growth signaling factor, inhibit GSK3β growth negative regulator, promote cell proliferation (CCK8 test), increase the secretion level of vascular endothelial growth factor (VEGF), reduce androgen receptor levels, and reduce the secretion of IL-6, IL-1, and TGF-β1, thereby activating the proliferation and differentiation of hair follicle stem cells, enhancing hair follicle vitality, and achieving the effect of promoting hair growth. Meanwhile, the components of the traditional Chinese medicine composition of the present invention have mild properties, avoiding the side effects that may be caused by chemical substances in the prior art, and can provide a milder, more effective, safe and stable treatment plan for hair loss.

[0281] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.

Claims

1. The application of a traditional Chinese medicine composition in the preparation of products for improving hair loss, characterized in that, The herbal composition includes wolfberry, jujube, poria cocos, coix seed, longan pulp, mulberry, and lotus seed.

2. The application according to claim 1, characterized in that, By weight, the traditional Chinese medicine composition comprises 1-5 parts of Poria cocos, 0.5-3 parts of Lycium barbarum, 0.5-3 parts of Morus alba, 0.5-3 parts of Longan aril, 0.01-2 parts of Coix lacryma-jobi, 0.01-2 parts of Nelumbo nucifera and 0.01-2 parts of Ziziphus jujuba; Preferably, the traditional Chinese medicine composition includes the wolfberry, the jujube, the poria cocos, the coix seed, the longan pulp, the mulberry, the black fungus, and the lotus seed; Preferably, by weight, the traditional Chinese medicine composition comprises 0.5-4 parts of the black fungus, 1-5 parts of the poria cocos, 0.5-3 parts of the wolfberry, 0.5-3 parts of the mulberry, 0.5-3 parts of the longan pulp, 0.01-2 parts of the coix seed, 0.01-2 parts of the lotus seed, and 0.01-2 parts of the jujube; Preferably, by weight, the traditional Chinese medicine composition includes 2-4 parts of the black fungus, 1-3 parts of the poria cocos, 1-3 parts of the wolfberry, 1-3 parts of the mulberry, 0.5-2 parts of the longan pulp, 0.05-0.2 parts of the coix seed, 0.05-2 parts of the lotus seed and 0.05-2 parts of the jujube.

3. The application according to claim 1, characterized in that, The improvement of hair loss includes increasing one or more of the following indicators: number of hairs, hair length, hair follicle width, or skin thickness.

4. The application according to claim 1, characterized in that, The improvement of hair loss includes regulating any one or more of the following indicators: upregulating the expression of cell proliferation-active factors, downregulating cell apoptosis levels, downregulating dihydrotestosterone secretion levels, upregulating β-catenin expression, downregulating glycogen synthesis kinase 3β expression, promoting cell proliferation, increasing vascular endothelial growth factor levels, decreasing androgen receptor levels, and decreasing inflammatory factor levels. Preferably, the inflammatory factors include one or more of interleukin-1, interleukin-6, or TGF-β1.

5. The application according to claim 1, characterized in that, The product dosage form includes oral preparations; Preferably, the oral preparation includes granules, tablets, capsules, solid beverages, or oral liquids.

6. The application of a traditional Chinese medicine composition in the preparation of products that increase hair follicle thickness, characterized in that, The traditional Chinese medicine composition includes wolfberry, jujube, poria cocos, coix seed, longan pulp, mulberry, and lotus seed; Preferably, by weight, the traditional Chinese medicine composition comprises 1-5 parts of Poria cocos, 0.5-3 parts of Lycium barbarum, 0.5-3 parts of Morus alba, 0.5-3 parts of Longan aril, 0.01-2 parts of Coix lacryma-jobi, 0.01-2 parts of Nelumbo nucifera and 0.01-2 parts of Ziziphus jujuba; Preferably, the traditional Chinese medicine composition includes the wolfberry, the jujube, the poria cocos, the coix seed, the longan pulp, the mulberry, the black fungus, and the lotus seed; Preferably, by weight, the traditional Chinese medicine composition comprises 0.5-4 parts of the black fungus, 1-5 parts of the poria cocos, 0.5-3 parts of the wolfberry, 0.5-3 parts of the mulberry, 0.5-3 parts of the longan pulp, 0.01-2 parts of the coix seed, 0.01-2 parts of the lotus seed, and 0.01-2 parts of the jujube; Preferably, by weight, the traditional Chinese medicine composition includes 2-4 parts of the black fungus, 1-3 parts of the poria cocos, 1-3 parts of the wolfberry, 1-3 parts of the mulberry, 0.5-2 parts of the longan pulp, 0.05-0.2 parts of the coix seed, 0.05-2 parts of the lotus seed and 0.05-2 parts of the jujube.

7. The application of a traditional Chinese medicine composition in the preparation of products that increase skin thickness, characterized in that, The traditional Chinese medicine composition includes wolfberry, jujube, poria cocos, coix seed, longan pulp, mulberry, and lotus seed; Preferably, by weight, the traditional Chinese medicine composition comprises 1-5 parts of Poria cocos, 0.5-3 parts of Lycium barbarum, 0.5-3 parts of Morus alba, 0.5-3 parts of Longan aril, 0.01-2 parts of Coix lacryma-jobi, 0.01-2 parts of Nelumbo nucifera and 0.01-2 parts of Ziziphus jujuba; Preferably, the traditional Chinese medicine composition includes the wolfberry, the jujube, the poria cocos, the coix seed, the longan pulp, the mulberry, the black fungus, and the lotus seed; Preferably, by weight, the traditional Chinese medicine composition comprises 0.5-4 parts of the black fungus, 1-5 parts of the poria cocos, 0.5-3 parts of the wolfberry, 0.5-3 parts of the mulberry, 0.5-3 parts of the longan pulp, 0.01-2 parts of the coix seed, 0.01-2 parts of the lotus seed, and 0.01-2 parts of the jujube; Preferably, by weight, the traditional Chinese medicine composition includes 2-4 parts of the black fungus, 1-3 parts of the poria cocos, 1-3 parts of the wolfberry, 1-3 parts of the mulberry, 0.5-2 parts of the longan pulp, 0.05-0.2 parts of the coix seed, 0.05-2 parts of the lotus seed and 0.05-2 parts of the jujube.

8. The application of a traditional Chinese medicine composition in the preparation of products that promote hair growth, characterized in that, The traditional Chinese medicine composition includes wolfberry, jujube, poria cocos, coix seed, longan pulp, mulberry, and lotus seed; Preferably, by weight, the traditional Chinese medicine composition comprises 1-5 parts of Poria cocos, 0.5-3 parts of Lycium barbarum, 0.5-3 parts of Morus alba, 0.5-3 parts of Longan aril, 0.01-2 parts of Coix lacryma-jobi, 0.01-2 parts of Nelumbo nucifera and 0.01-2 parts of Ziziphus jujuba; Preferably, the traditional Chinese medicine composition includes the wolfberry, the jujube, the poria cocos, the coix seed, the longan pulp, the mulberry, the black fungus, and the lotus seed; Preferably, by weight, the traditional Chinese medicine composition comprises 0.5-4 parts of the black fungus, 1-5 parts of the poria cocos, 0.5-3 parts of the wolfberry, 0.5-3 parts of the mulberry, 0.5-3 parts of the longan pulp, 0.01-2 parts of the coix seed, 0.01-2 parts of the lotus seed, and 0.01-2 parts of the jujube; Preferably, by weight, the traditional Chinese medicine composition includes 2-4 parts of the black fungus, 1-3 parts of the poria cocos, 1-3 parts of the wolfberry, 1-3 parts of the mulberry, 0.5-2 parts of the longan pulp, 0.05-0.2 parts of the coix seed, 0.05-2 parts of the lotus seed and 0.05-2 parts of the jujube.

9. The use of a composition in the preparation of a product for improving hair loss, characterized in that, The composition comprises composition A and composition B; The composition A includes wolfberry, jujube, poria cocos, coix seed, longan pulp, mulberry, and lotus seed; Composition B includes one or more of the following: Platycladus orientalis leaves, Polygonum multiflorum, Anemarrhena asphodeloides, Eclipta prostrata, Sophora flavescens, Saposhnikovia divaricata, Phellodendron chinense, Rehmannia glutinosa, or flaxseed. Preferably, by weight, composition A comprises 1-5 parts of Poria cocos, 0.5-3 parts of Lycium barbarum, 0.5-3 parts of mulberry, 0.5-3 parts of longan pulp, 0.01-2 parts of Coix seed, 0.01-2 parts of lotus seed and 0.01-2 parts of jujube; Preferably, the composition A includes the wolfberry, the jujube, the poria cocos, the coix seed, the longan pulp, the mulberry, the black fungus, and the lotus seed; Preferably, by weight, composition A comprises 0.5-4 parts of the black fungus, 1-5 parts of the poria cocos, 0.5-3 parts of the wolfberry, 0.5-3 parts of the mulberry, 0.5-3 parts of the longan pulp, 0.01-2 parts of the coix seed, 0.01-2 parts of the lotus seed, and 0.01-2 parts of the jujube; Preferably, by weight, composition A comprises 2-4 parts of the black fungus, 1-3 parts of the poria cocos, 1-3 parts of the wolfberry, 1-3 parts of the mulberry, 0.5-2 parts of the longan pulp, 0.05-0.2 parts of the coix seed, 0.05-2 parts of the lotus seed and 0.05-2 parts of the jujube.

10. The application according to claim 9, characterized in that, The composition B includes the arborvitae leaf, the fleeceflower root, the anemarrhena rhizome, the eclipta prostrata, the sophora flavescens root, the saposhnikovia root, the phellodendron bark, the rehmannia root, and the flaxseed; Preferably, by weight, composition B comprises 0.1-3 parts of the Platycladus orientalis leaves, 0.1-2.5 parts of Polygonum multiflorum, 0.05-2 parts of Anemarrhena asphodeloides, 0.01-0.15 parts of Eclipta prostrata, 0.005-0.1 parts of Sophora flavescens, 0.01-0.15 parts of Saposhnikovia divaricata, 0.01-0.15 parts of Phellodendron chinense, 0.01-0.2 parts of Rehmannia glutinosa, and 0.001-1 parts of flaxseed.

Images